BOSTON, Mass., June 26, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as “natural hotspots,” today announced it will present preclinical data from the Company’s CARD11-BCL10-MALT1 (CBM) program in two poster presentations at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, taking place July 2-5, 2025, in Barcelona, Spain.
Presentation details are as follows:
Title: Synthetic lethality of CBM signalosome inhibition for KRAS-Mutant Colorectal Cancers
Poster Number: 124P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 15:30-16:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain
Title: Novel CBM signalosome inhibitor revealed the essentiality of CBM signalosome for KRAS mutant colorectal cancer
Poster Number: 125P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 15:30-16:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called “natural hotspots.” These pockets are decisive in controlling a protein’s cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company’s proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases and cancer. To learn more, visit www.hotspotthera.com.
HotSpot Investor & Media Contact:
Natalie Wildenradt